Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2018
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2018, provides an overview of the Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline landscape.
Heart failure is also known as congestive heart failure (CHF). CHF is a condition in which the heart is no longer able to pump out enough oxygen-rich blood. Symptoms include cough, fatigue, weakness, faintness, loss of appetite, swollen (enlarged) liver or abdomen, swollen feet and ankles and weight gain. There are two types of heart failure including systolic heart failure (left ventricle loses its ability to contract normally) and diastolic heart failure (left ventricle loses its ability to relax normally). The predisposing factors include high blood pressure, diabetes, sleep apnea, alcohol use and irregular heartbeats. Treatment includes surgery, vasodilator, beta blockers and diuretics.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 14, 28, 19, 3, 49, 13 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 21 and 4 molecules, respectively.
Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure) (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Congestive Heart Failure (Heart Failure) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Congestive Heart Failure (Heart Failure) (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Congestive Heart Failure (Heart Failure) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Heart Failure) (Cardiovascular)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Congestive Heart Failure (Heart Failure) (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2018
Table of Contents
Table of Contents 2
Introduction 6
Congestive Heart Failure (Heart Failure) - Overview 7
Congestive Heart Failure (Heart Failure) - Therapeutics Development 8
Congestive Heart Failure (Heart Failure) - Therapeutics Assessment 29
Congestive Heart Failure (Heart Failure) - Companies Involved in Therapeutics Development 43
Congestive Heart Failure (Heart Failure) - Drug Profiles 74
Congestive Heart Failure (Heart Failure) - Dormant Projects 385
Congestive Heart Failure (Heart Failure) - Discontinued Products 392
Congestive Heart Failure (Heart Failure) - Product Development Milestones 394
Appendix 404
List of Tables
Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Products under Development by Companies, H1 2018 (Contd..7), H1 2018
Products under Development by Universities/Institutes, H1 2018
Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Acorda Therapeutics Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Actelion Pharmaceuticals Ltd, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Adrenomed AG, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Amgen Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Araim Pharmaceuticals Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Arbor Pharmaceuticals LLC, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Ascendia Pharmaceuticals LLC, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by AstraZeneca Plc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Athersys Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Bayer AG, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by BEAT BioTherapeutics Corp, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by BioCardia Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by BlueRock Therapeutics, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Bristol-Myers Squibb Co, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by C&C BioPharma LLC, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Capricor Therapeutics Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Celixir Ltd, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by FibroGen Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Galenica Ltd, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by GlaxoSmithKline Plc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Hemostemix Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Immunwork Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Innopharmax Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Intra-Cellular Therapies Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Ironwood Pharmaceuticals Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Juventas Therapeutics Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by La Jolla Pharmaceutical Company, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Lead Discovery Center GmbH, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Les Laboratoires Servier SAS, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Lexicon Pharmaceuticals Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Madeleine Pharmaceuticals Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Merck & Co Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Mesoblast Ltd, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Miragen Therapeutics Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Moderna Therapeutics Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by MorphoSys AG, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by N-Gene Research Laboratories Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by NanoCor Therapeutics Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Novartis AG, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Otsuka Holdings Co Ltd, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Oxstem Ltd, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Palatin Technologies Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Pfizer Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by PharmaIN Corp, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by PhaseBio Pharmaceuticals Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Recardio GmbH, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Renova Therapeutics Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Ribomic Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Sanofi, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Sarfez Pharmaceuticals Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Savara Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by scPharmaceuticals Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Stealth BioTherapeutics Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Stemedica Cell Technologies Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Theravance Biopharma Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by TiGenix NV, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Trevena Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by U.S. Stem Cell Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Vicore Pharma AB, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by XyloCor Therapeutics Inc, H1 2018
Congestive Heart Failure (Heart Failure) - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H1 2018
Congestive Heart Failure (Heart Failure) - Dormant Projects, H1 2018
Congestive Heart Failure (Heart Failure) - Dormant Projects, H1 2018 (Contd..1), H1 2018
Congestive Heart Failure (Heart Failure) - Dormant Projects, H1 2018 (Contd..2), H1 2018
Congestive Heart Failure (Heart Failure) - Dormant Projects, H1 2018 (Contd..3), H1 2018
Congestive Heart Failure (Heart Failure) - Dormant Projects, H1 2018 (Contd..4), H1 2018
Congestive Heart Failure (Heart Failure) - Dormant Projects, H1 2018 (Contd..5), H1 2018
Congestive Heart Failure (Heart Failure) - Dormant Projects, H1 2018 (Contd..6), H1 2018
Congestive Heart Failure (Heart Failure) - Discontinued Products, H1 2018
Congestive Heart Failure (Heart Failure) - Discontinued Products, H1 2018 (Contd..1), H1 2018
List of Figures
Number of Products under Development for Congestive Heart Failure (Heart Failure), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
Global Antioxidant Vitamins Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 100
The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
Global Clavulanate Potassium Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 86
The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030.
North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
Global Amoxicillin Sodium Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 84
The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030.
North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
Global Melatonin Supplements Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 106
The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 93
The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
Global Sleeping Pills Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 94
The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
Global Zinc Oral Drops Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 85
The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
Global Zinc Drops Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 85
The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
Global Anti-Infectives Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 78
The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
